Table 1.

Therapeutics That Target Lipid Raft-Associated Factors

Therapeutics	Targets	Cancer cell type	References
Edelfosine	Fas, JNK, Hsp90	Leukemia, multiple myeloma,	Gajate and Mollinedo, 2001; Gajate et al., 2004; Gajate et al., 2009; Gajate and Mollinedo, 2007 Gajate et al., 1998; Nieto-Miguel et al., 2008
Resveratrol	Fas, TRAIL	Multiple myeloma, T-cell leukemia	Reis-Sobreiro et al., 2009
Avicin D	Fas	T-cell leukemia	Xu et al., 2009
Cisplatin	Fas	Colon	Lacour et al., 2004
Perifosine	Fas	Multiple myeloma	Gajate and Mollinedo, 2007
Agonist T0901317	Liver X receptor, AKT	Prostate	Pommier et al., 2010
Rituximab/Rituxan	CD20	Non-Hodgkin's B-cell lymphoma	Janas et al., 2005
7-ketocholesterol	Trpc-1	Monocytic leukemia	Berthier et al., 2004
Stearylamine-liposomes	PKCδ		Arisaka et al., 2011
Anti-CD5 antibody	CD5	Chronic lymphocytic leukemia	Renaudineau et al., 2005
MβCD, simvastatin, filipin III and 5-cholesten-5-β-ol	AKT	Prostate	Calay et al., 2010